Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 20, 2011 07:00 ET | Source: Depomed, Inc.

Depomed, Inc. Selects inVentiv Health to Provide Sales Team for Gralise(TM)

BURLINGTON, Mass. and MENLO PARK, Calif., June 20, 2011 (GLOBE NEWSWIRE) -- inVentiv Health, offering best-in-class clinical, consulting and commercial services to the healthcare industry, and...
April 12, 2011 17:26 ET | Source: Depomed, Inc.

New Analyses of Safety and Efficacy Data of Depomed's Gralise(TM) to be Presented at the 63rd Annual Meeting of the American Academy of Neurology

MENLO PARK, Calif., April 12, 2011 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) today announced that two new analyses of phase 3 clinical data of Gralise™ (gabapentin), a once-daily evening...
March 03, 2011 16:05 ET | Source: Depomed, Inc.

Depomed Reports Fourth Quarter and Year-End 2010 Financial Results

MENLO PARK, Calif., March 3, 2011 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) today reported financial results for the fourth quarter and year ended December 31, 2010. "We are pleased to report...
March 03, 2011 04:00 ET | Source: Depomed, Inc.

Depomed Completes Enrollment of Breeze 3 Phase 3 Clinical Trial for Non-Hormonal Treatment in Menopausal Hot Flashes

MENLO PARK, Calif., March 3, 2011 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) announced today that it has completed enrollment of Breeze 3, the company's pivotal Phase 3 clinical trial evaluating...
January 28, 2011 19:30 ET | Source: Depomed, Inc.

Depomed Announces US Food and Drug Administration Approval of GRALISE(TM) (gabapentin) Once-Daily Tablets for Treatment of Post-Herpetic Neuralgia

MENLO PARK, Calif., Jan. 28, 2011 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) today announced that US FDA has approved GRALISE™ (gabapentin) Tablets for once-daily treatment of post-herpetic...
January 18, 2011 16:05 ET | Source: Depomed, Inc.

Depomed Will Engage in Mediation to Resolve Dispute With Abbott; Comments on DM-1796 Regulatory Status and Orphan Drug Designation

MENLO PARK, Calif., Jan. 18, 2011 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) today announced that it will engage in a mediation process with Abbott Products, Inc., regarding Abbott's...
September 17, 2010 17:59 ET | Source: Depomed, Inc.

Depomed to Present at the UBS Global Life Sciences Conference and the Fifth Annual JMP Securities Healthcare Conference

MENLO PARK, Calif., Sept. 17, 2010 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) announced today that its president and chief executive officer, Carl A. Pelzel will be presenting at the UBS Global...
September 09, 2010 07:00 ET | Source: Depomed, Inc.

Depomed to Present at the Rodman & Renshaw 12th Annual Healthcare Conference

MENLO PARK, Calif., Sept. 9, 2010 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) announced today that its president and chief executive officer, Carl A. Pelzel will be presenting at the Rodman &...
August 11, 2010 07:00 ET | Source: Depomed, Inc.

Depomed Reaches SPA Agreement With FDA for Phase 3 Hot Flash Trial

MENLO PARK, Calif., Aug. 11, 2010 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special...
August 05, 2010 16:40 ET | Source: Depomed, Inc.

Depomed Licenses GLUMETZA(R) Data and Acuform(R) Technology

MENLO PARK, Calif., Aug. 5, 2010 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) today announced that Janssen Pharmaceutica N.V. has licensed worldwide rights to Depomed's Acuform® gastric...